戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 to oral eliglustat, a selective inhibitor of glucosylceramide synthase.
2 lic conversion by sphingomyelin synthase and glucosylceramide synthase.
3 argeted disruption of the Ugcg gene encoding glucosylceramide synthase.
4 quitous glycosphingolipid (GSL) generated by glucosylceramide synthase, a key regulatory enzyme encod
5 yldeoxynojirimycin (NB-DNJ), an inhibitor of glucosylceramide synthase, a pivotal enzyme in the early
6 ceptor), and TNF-stimulated Gb3 synthase and glucosylceramide synthase activities but did not affect
7  0.01); both serine palmitoyltransferase and glucosylceramide synthase activities remained unaltered.
8      Because both sphingomyelin synthase and glucosylceramide synthase activities were significantly
9   4'-Hydroxy-P4 and ethylenedioxy-P4 blocked glucosylceramide synthase activity at concentrations tha
10 d by fumonisin B(1) and by overexpression of glucosylceramide synthase; again implicating endogenous
11 ed by PDMP cannot be caused by inhibition of glucosylceramide synthase alone.
12 mal developmental increases in activities of glucosylceramide synthase and cholesterol sulfotransfera
13 lamino-3-morpholino-1-propanol.HCI (PDMP), a glucosylceramide synthase and LacCer synthase (galactosy
14 lamino-3-morpholino-1-propanol.HCl (PDMP), a glucosylceramide synthase and LacCer synthase (GalT-2) i
15 pholino-1-propanol (D-PDMP), an inhibitor of glucosylceramide synthase and lactosylceramide synthase
16 a genome-wide forward screen that shows that glucosylceramide synthase and other components of the ga
17 ol (PDMP), which inhibits acid ceramidase or glucosylceramide synthase and then increases endogenous
18              D-PDMP is a potent inhibitor of glucosylceramide synthase and thereby the synthesis of c
19 ed the glycosphingolipid biosynthesis enzyme glucosylceramide synthase as a direct transcriptional LX
20 s compound, D-threo-4'-hydroxy-P4, inhibited glucosylceramide synthase at an IC50 of 90 nM.
21    d-t-EtDO-P4 has the advantage of blocking glucosylceramide synthase at low nanomolar concentration
22   Our results suggest that (a) inhibition of glucosylceramide synthase does not reverse multidrug res
23 n treatment with brain-permeant inhibitor of glucosylceramide synthase, effects mediated via improved
24                        Conversely, silencing glucosylceramide synthase expression disrupts Gb3 synthe
25 holesterol and glycosphingolipids, including glucosylceramide synthase (GCS) (gene Ugcg)-derived gang
26 n mammalian sphingomyelin synthase (SMS) and glucosylceramide synthase (GCS) and yeast inositol phosp
27                                              Glucosylceramide synthase (GCS) catalyzes the transfer o
28 c:ceramide glucosyltransferase (EC 2.4.1.80; glucosylceramide synthase (GCS) from a rat liver and pre
29          Here, we investigated the merits of glucosylceramide synthase (GCS) inhibition as a potentia
30                                              Glucosylceramide synthase (GCS) inhibitors, including th
31     32 (EXEL-0346) represents a new class of glucosylceramide synthase (GCS) inhibitors.
32            In this study, we have introduced glucosylceramide synthase (GCS) into wild type MCF-7 bre
33                                              Glucosylceramide synthase (GCS) is a rate-limiting enzym
34                                              Glucosylceramide synthase (GCS) transfers glucose from U
35 golipid metabolism pathway via inhibition of glucosylceramide synthase (GCS) using a CNS-penetrant sm
36                            Overexpression of glucosylceramide synthase (GCS), a pivotal enzyme in gly
37              Ceramide glycosylation, through glucosylceramide synthase (GCS), allows cellular escape
38 native approach that involves suppression of glucosylceramide synthase (GCS), an enzyme that glycosyl
39 other glucosylceramide metabolizing enzymes, glucosylceramide synthase (GCS), lysosomal glucosylceram
40                                   The enzyme glucosylceramide synthase (GCS), responsible for bioacti
41  with BFT in the presence of an inhibitor of glucosylceramide synthase (GCS), the enzyme responsible
42                                              Glucosylceramide synthase (GCS), the enzyme responsible
43 s was achieved by cellular transfection with glucosylceramide synthase (GCS), the enzyme that convert
44 through up-regulating the gene expression of glucosylceramide synthase (GCS).
45 the human beta-glucosidases GBA and GBA2 and glucosylceramide synthase (GCS).
46 tiviral effect of two specific inhibitors of glucosylceramide synthase (GCS): (i) Genz-123346, an ana
47               Since clearance is mediated by glucosylceramide synthase (GCS, EC 2.4.1.80) levels of t
48            Microarray data demonstrated that glucosylceramide synthase (GCS; glucosylceramide transfe
49 olipid C9-methyltransferases (SmtA/SmtB) and glucosylceramide synthase (GcsA) to fungal phenotypes, s
50 n CD4(+) T cells using a potent inhibitor of glucosylceramide synthase (Genz-122346) led to a moderat
51 hibiting glycolipid biosynthesis by blocking glucosylceramide synthase has been proposed to reverse d
52 hance insulin signaling, but those targeting glucosylceramide synthase have no effect.
53 ecific deficiency in Ugcg, the gene encoding glucosylceramide synthase (hUgcg-/- mice).
54                         3) Overexpression of glucosylceramide synthase in myotubes induces glucosylce
55  work delineates both the mechanism by which glucosylceramide synthase inhibition prevents autophagic
56                 These findings indicate that glucosylceramide synthase inhibition with venglustat mig
57        In the Zucker diabetic fatty rat, the glucosylceramide synthase inhibitor (1R,2R)-nonanoic aci
58   Here we show that oral administration of a glucosylceramide synthase inhibitor (GCSi) reduces plasm
59 e induction of T-cell apoptosis, because the glucosylceramide synthase inhibitor (PPPP) significantly
60  ceramide synthase inhibitor fumonisin B1 or glucosylceramide synthase inhibitor 1-phenyl-2-decanoyla
61 D4 and various chemokine receptors, with the glucosylceramide synthase inhibitor 1-phenyl-2-hexadecan
62 yristoylphosphatidylcholine liposome and the glucosylceramide synthase inhibitor D-PDMP induced cell
63                                          The glucosylceramide synthase inhibitor ethylenedioxyphenyl-
64                                          The glucosylceramide synthase inhibitor Genz-123346 inhibite
65         Inhibition of GSL synthesis with the glucosylceramide synthase inhibitor Genz-667161 decrease
66              Venglustat is a brain-penetrant glucosylceramide synthase inhibitor that, in previous st
67  earlier studies utilized a first generation glucosylceramide synthase inhibitor to deplete cells of
68 stat is an investigational, brain-penetrant, glucosylceramide synthase inhibitor with potential to im
69 ssion was reduced approximately 40% with the glucosylceramide synthase inhibitor, d-threo-1-phenyl-2-
70          Complications observed with another glucosylceramide synthase inhibitor, N-butyldeoxynojirim
71 lioside synthesis in SK-RC-45 cells with the glucosylceramide synthase inhibitor, PPPP, protected T c
72 a U.S. Food and Drug Administration-approved glucosylceramide synthase inhibitor, reduced osteoclast-
73 lene, antagonists of Ryrs and by Genz-161, a glucosylceramide synthase inhibitor, suggesting substrat
74 ), proteases (trypsin and chymotrypsin), and glucosylceramide synthase inhibitors (dl-threo-1-phenyl-
75                              A new series of glucosylceramide synthase inhibitors based on substituti
76 both multidrug-resistant cell lines with the glucosylceramide synthase inhibitors PDMP (d-threo-1-phe
77 rs C9DGJ and C4DGJ, which are more selective glucosylceramide synthase inhibitors than PDMP, failed t
78           Recently, more active and specific glucosylceramide synthase inhibitors, including d-threo-
79 nant glucocerebrosidase and orally-available glucosylceramide synthase inhibitors.
80 ition, R28 retinal neurons were treated with glucosylceramide synthase inhibitors.
81       Glucosylation of ceramide catalyzed by glucosylceramide synthase is the entry step for the form
82 3-morpholino-1-propanol HCl, an inhibitor of glucosylceramide synthase, markedly abrogated gangliosid
83 irimycin derivatives on their merits as dual glucosylceramide synthase/neutral glucosylceramidase inh
84 xample, either ganglioside addition or human glucosylceramide synthase overexpression suppresses insu
85 iprocally modulated by chronic palmitate and glucosylceramide synthase overexpression.
86                      Thus, overexpression of glucosylceramide synthase, previously shown to protect a
87   Brain-permeant small-molecule inhibitor of glucosylceramide synthase reduced the accumulation of bi
88 hreo-ethylenedioxyphenyl-P4, an inhibitor of glucosylceramide synthase, restored cholesterol in cultu
89 dentified sites of action: the inhibition of glucosylceramide synthase, resulting in the depletion of
90  A null mutation of the FgGCS1 gene encoding glucosylceramide synthase results in a mutant lacking gl
91  of knockout mice with a potent inhibitor of glucosylceramide synthase reversed accumulation of globo
92                                Inhibitors of glucosylceramide synthase, sphingomyelin synthase, and c
93                      In cell-free assays for glucosylceramide synthase, tamoxifen (1:10 molar ratio w
94 s are considerably more potent inhibitors of glucosylceramide synthase than their aliphatic counterpa
95 s led to the identification of inhibitors of glucosylceramide synthase, the enzyme catalyzing the fir
96 ted for 7 weeks with a specific inhibitor of glucosylceramide synthase, the initial enzyme involved i
97 lts provide proof of principle for targeting glucosylceramide synthase to decrease gangliosides as a
98                We used a potent inhibitor of glucosylceramide synthase to test whether substrate depr
99    D-threo-3', 4'-Ethylenedioxy-P4-inhibited glucosylceramide synthase was comparably active to the p
100  the potency of these inhibitors in blocking glucosylceramide synthase was primarily dependent upon t
101           Sphingomyelin synthase, as well as glucosylceramide synthase, was inactivated by PDT in bot
102 pholino-1-propanol (D-PDMP) (an inhibitor of glucosylceramide synthase) were reduced by >90%.
103 ecanoylamino-3 -pyrrolidino-1-propanol-HC l (glucosylceramide synthase), which depletes cellular gang
104      Finally, stable overexpression of human glucosylceramide synthase, which attenuates ceramide lev
105 tat, a small iminosugar, reversibly inhibits glucosylceramide synthase, which catalyses the first com
106 ort that ceramide glycosylation catalyzed by glucosylceramide synthase, which is enhanced in breast c

 
Page Top